Effect of gene polymorphism of ghrelin on the risk of essential hypertension in a japanese population

Abstract

with a history of diabetes, CKD, and diastolic blood pressure 90 mm Hg. Baseline REGARDS data were collected during telephone interviews and in-home study visits in 2003 through 2007 and included two blood pressure measurements following a standardized protocol. SBP was categorized as < 140 mm Hg, 140-149 mm Hg, and 150 mm Hg. Outcomes were identified through December 31, 2011 using primary data collection and Medicare claims. Of the 2,279 REGARDS participants taking antihypertensive medications with Medicare linked data (mean age 72.2 years, 54.8% female), 309 (13.6%) had SBP of 140 to 149 mm Hg and 200 (8.8%) had SBP 150 mm Hg. After multivariable adjustment, SBP of 140 to 149 mm Hg versus SBP < 140 mm Hg was not associated with any of the outcomes (Table 1) whereas SBP 150 mm Hg was associated with an increased risk for CVD. In summary, SBP levels between 140 and 149 mm Hg were not associated with CVD-related outcomes or falls in comparison to SBP < 140 mm Hg among adults 65 years taking antihypertensive medication. These data suggest the higher SBP threshold for treatment initiation and goal attainment among individuals 65 years of age without a history of diabetes or CKD, with DBP 90 mm Hg may be safe.